Due to its reversible nature, Takotsubo cardiomyopathy (TTC) is considered an intriguing and fascinating cardiovascular disease characterized by a transient wall motion abnormality of the left ventricle, affecting more than one coronary artery territory, often in a circumferential apical distribution. Takotsubo cardiomyopathy was discovered by a Japanese cardiovascular expert and classified as acquired primary cardiomyopathy by the American Heart Association (AHA) in 1990 and 2006, respectively. Regardless of the extensive research efforts, its pathophysiology is still unclear; therefore, there are no well-established guidelines specifically for treating and managing TTC patients. Increasing evidence suggests that sympatho-adrenergic stimulation is strongly associated with the pathogenesis of this disease. Under acute stressful conditions, the hyperstimulation of beta-adrenergic receptors (β-ARs) resulting from excessive release of catecholamines induces intracellular kinases capable of phosphorylating and activating “A Disintegrin and Metalloprotease 17” (ADAM17), a type-I transmembrane protease that plays a central role in acute myocardial inflammation and metabolic lipids dysregulation which are the main hallmarks of TTC. However, our understanding of this is limited; hence this concise review provides a comprehensive insight into the key role of ADAM17 in acute myocardial inflammation and metabolic lipids dysregulation during acute stress. Also, how the synergy of ADAM17-induced acute inflammation and lipids dysregulation causes TTC is explained. Finally, potential therapeutic targets for TTC are also discussed.
25 November 2021 in Frontiers in Cardiovascular Medicine
The increasing incidence of stress-induced cardiomyopathy is due to the complexities of our modern-day lives, which constantly elicit stress responses. Herein, we aimed to explore the therapeutic potential of Amlexanox and Forskolin in promoting the recovery from stress-induced cardiomyopathy. Isoproterenol-induced cardiomyopathy (ICM) models were made, and the following treatment interventions were administered: 5% v/v DMSO as a placebo, Amlexanox (2.5 mg/100 g/day) treatment, Forskolin (0.5 mg/100 g/day), and Amlexanox and Forskolin combination, at their respective aforementioned dosages. The effects of Amlexanox and Forskolin treatment on ICM models were assessed by eletrocardiography and echocardiography. Also, using histological analysis and ELISA, their impact on myocardial architecture and inflammation were ascertained. ICM mice had excessive myocardial fibrosis, hypertrophy, and aggravated LVSDs which were accompanied by massive CD86+ inflammatory cells infiltration. Amlexanox treatment attenuated the myocardial hypertrophy, fibrosis, and inflammation and also slightly improved systolic functions. Meanwhile, forskolin treatment resulted in arrhythmias but significantly enhanced the resolution of myocardial fibrosis and inflammation. Intriguingly, Amlexanox and Forskolin combination demonstrated the most potency at promoting the recovery of the ICM from LVSD by attenuating maladaptive myocardial hypertrophy, fibrosis, and inflammatory responses. Our findings highlight the Amlexanox and Forskolin combination as a potential therapeutic intervention for enhancing cardiac function recovery from stress-induced cardiomyopathy by promoting the resolution of maladaptive cardiac remodeling.
Background and Purpose: The immune system is implicated in the pathogenesis of pathological cardiac hypertrophy (PCH). However, there is currently no therapeutic intervention to prevent PCH. Here, we aimed at preventing pathological cardiac hypertrophy (PCH) during chronic catecholamine stress via modulating adaptive inflammatory by targeting adenylyl cyclases (ACs) and G protein-coupled receptor kinase 5 (GRK5) in cardiomyocytes and immune cells. Experimental Approach: PCH was induced in mice by chronic isoproterenol injections. In vitro, peritoneal macrophages were challenged with lipopolysaccharide under stress. Further experiments employed the therapeutic interventions Amlexanox and Forskolin to inhibit GRK5 and activate ACs-cAMP, respectively. Cardiac functions were assessed with echocardiography. Inflammatory markers were assessed with ELISA and RT-qPCR (in vivo and in vitro). GRK5 localizations in macrophages were assessed by immunofluorescence, and alterations in protein expression were analyzed with immunoblotting. Histological assessments were done with Masson, H&E and IHC staining. Key Results: PCH mice had deteriorating cardiac functions and morphological remodeling, accompanied by massive immune cell infiltrations. Similarities were observed proinflammatory markers upregulation, as were IL-10 found downregulated both in vivo and in vitro. However, the combination of Amlexanox and Forskolin modulated adaptive inflammatory responses and also maintained proper cardiac morphology and function. The single therapies of neither Amlexanox nor Forskolin were able to attain the aforementioned with much efficacy as their combination therapy. Conclusion: The combination therapy of ALX and FSK has the therapeutic potential of preventing the occurrence of pathological cardiac hypertrophy during CCS by modulating adaptive inflammatory responses while maintaining normal cardiac function.